Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus recommendation of “Hold” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $24.50.

A number of brokerages have commented on ATXS. Evercore ISI reiterated an “outperform” rating and set a $26.00 target price on shares of Astria Therapeutics in a report on Wednesday, October 1st. HC Wainwright downgraded Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Wedbush set a $13.00 price objective on Astria Therapeutics and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Jefferies Financial Group lowered shares of Astria Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $30.00 to $13.00 in a report on Tuesday, October 14th. Finally, Lifesci Capital cut shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th.

Astria Therapeutics Trading Up 0.6%

Shares of ATXS opened at $12.58 on Friday. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $13.29. The stock has a market cap of $718.07 million, a P/E ratio of -5.88 and a beta of 0.01. The company has a 50-day moving average of $12.77 and a two-hundred day moving average of $9.83.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The firm had revenue of $0.71 million for the quarter, compared to analyst estimates of $10.67 million. As a group, analysts forecast that Astria Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of Astria Therapeutics by 4,607.1% during the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock worth $9,091,000 after purchasing an additional 1,660,039 shares during the last quarter. Vestal Point Capital LP lifted its position in Astria Therapeutics by 9.6% during the third quarter. Vestal Point Capital LP now owns 4,956,000 shares of the biotechnology company’s stock worth $36,080,000 after buying an additional 434,000 shares during the period. Nantahala Capital Management LLC boosted its stake in Astria Therapeutics by 59.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company’s stock worth $5,733,000 after buying an additional 400,000 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in Astria Therapeutics in the 2nd quarter valued at about $1,608,000. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Astria Therapeutics by 48.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company’s stock valued at $4,690,000 after buying an additional 286,800 shares during the period. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.